Panitumumab

С Википедије, слободне енциклопедије
Panitumumab
Klinički podaci
Prodajno imeVectibix, Vectibix (Amgen)
Drugs.comMonografija
Način primeneIntravenozno
Farmakokinetički podaci
Poluvreme eliminacije7,5 dana
Identifikatori
CAS broj339177-26-3 ДаY
ATC kodL01XC08 (WHO)
DrugBankDB01269 ДаY
ChEMBLCHEMBL1201827 ДаY
Hemijski podaci
FormulaC6398H9878N1694O2016S48
Molarna masa144.324,12 g·mol−1

Panitumumab (INN), ranije ABX-EGF, je potpuno humanizovano monoklonalno antitelo koje je specifično za receptor epidermalnog faktora rasta (takođe poznat kao EGF receptor, EGFR, ErbB-1 i HER1 kod čoveka).[1][2][3][4][5][6][7]

Reference[уреди | уреди извор]

  1. ^ Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. PMID 14967460
  2. ^ Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. PMID 11255078
  3. ^ Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. PMID 18343240
  4. ^ Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. PMID 17355997
  5. ^ Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. PMID 20481659
  6. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  7. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958.  уреди

Literatura[уреди | уреди извор]

  • Amado, RG; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D. J.; Juan, T.; Sikorski, R.; Suggs, S. (2008). „Wild-Type KRAS is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer”. J Clin Onco. 26 (10): 1626—1634. doi:10.1200/JCO.2007.14.7116. 
  • Van Cutsem, E; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.-L.; Van Laethem, J.-L.; Maurel, J. (2007). „Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer”. J Clin Onco. 25 (13): 1658—1664. doi:10.1200/JCO.2006.08.1620. 

Spoljašnje veze[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).
Преузето из „https://sr.wikipedia.org/w/index.php?title=Panitumumab&oldid=27603889”